The content on this site is intended for healthcare professionals only
Prof Bullinger speaks with ecancer at EHA 23 about the clinical implications for mutations detected in AML patients cells.
He highlights key mutations including p53, IDH and Flt3 mutations, some of which are treatable with targeted agents such as midostaurin, others acting as prognostic markers.
He highlights the impact of kinase inhibitors on survival, and the factors of age and persistent disease in treatment management.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
Oncologists' perspectives and practices on minimal residual disease testing in multiple myeloma
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
A patient-reported questionnaire may eliminate the need for an ophthalmic exam before belantamab mafodotin dosing in TI NDMM
Importance of MRD in newly developed multiple myeloma
Best practice in HRRm testing in patients with metastatic prostate cancer
